SAN DIEGO – August 18, 2010 – Entest BioMedical Inc. (OTCBB:ENTB) today announced that it has identified five veterinary clinics as possible acquisition candidates. It is the intention of Entest to utilize these clinics as sources of near term revenue to be used to support research and development as well as distribution channels for products such as ImenVax™, the Company’s immuno-therapeutic canine cancer vaccine currently in development.
